PARP Inhibitors in Newly Diagnosed or Recurrent Ovarian Cancer Maintenance Therapy: Evidence of Efficacy and Safety from Randomized Controlled Trials. Biomed. Res. Ther. 2023, 10 (12), 6090-6102. https://doi.org/10.15419/bmrat.v10i12.851.